Benign gastric and duodenal ulcers including those complicating NSAID therapy, erosive reflux oesophagits and for disorders associated with hypersecretion of gastric acid, such as the Zollinger-Ellison syndrome.

Antiulcerant

Benign gastric and duodenal ulcers including those complication therapy : 20 mg daily for 4 weeks in duodenal ulceration or 8 weeks in gastric ulceration, in severe cases the dose may be increased to 40 mg daily; long-term use is not recommended. Healing of reflux oesophagitis : 20 mg daily for 4 weeks, followed by a further 4-8 weeks if not fully healed; 40 mg daily has been given for 8 weeks in reflux oesophagitis refractory to other treatment; may be continued at 20 mg daily. Zollinger-Ellison syndrome : Initially 60 mg once daily; usual range 20-120 mg daily (above 80 mg in 2 divided doses). Larger doses of upto 180 mg daily in divided doses may be used or as prescribed by the physicians.

There are no known contraindications to the use of Omeprazole.

Zilon® is well tolerated. Nausea, diarrhea, abdominal colic, paresthesia, dizziness and headache have been stated to be generally mild and transient and not requiring a reduction in dosage.

Avoid in pregnancy unless there is no safer altenative. Breast feeding should be discontinued if the use of Omeprazole is considered essential.

Symptomatic response to therapy with Omeprazole dose not preclude the presence of gastric malignancy. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with Omeprazole is instituted as treatment may alleviate symptoms and delay diagnosis.

Protect from light, store in dry place below 30∞ C.